Document Type
Article
Publication Date
3-1-2022
Abstract
The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to evaluate the role of crizotinib in rare tumors that harbored either ALK or ROS1 rearrangements. Patients with malignancies that progressed following at least one prior systemic therapy were accrued to the NCI-MATCH for molecular profiling, and those with actionable ALK or ROS1 rearrangements were offered participation in sub-protocols F or G, respectively. There were five patients who enrolled on Arm F (ALK) and four patients on Arm G (ROS1). Few grade 3 or 4 toxicities were noted, including liver test abnormalities, and acute kidney injury. For sub-protocol F (ALK), the response rate was 50% (90% CI 9.8-90.2%) with one complete response among the 4 eligible patients. The median PFS was 3.8 months, and median OS was 4.3 months. For sub-protocol G (ROS1) the response rate was 25% (90% CI 1.3-75.1%). The median PFS was 4.3 months, and median OS 6.2 months. Data from 3 commercial vendors showed that the prevalence of ALK and ROS1 rearrangements in histologies other than non-small cell lung cancer and lymphoma was rare (0.1% and 0.4% respectively). We observed responses to crizotinib which met the primary endpoint for ALK fusions, albeit in a small number of patients. Despite the limited accrual, some of the patients with these oncogenic fusions can respond to crizotinib which may have a therapeutic role in this setting.
Recommended Citation
Mansfield, A S; Wei, Z; Mehra, R; Shaw, A T; Lieu, C H; Forde, P M; Drilon, A E; Mitchell, Edith P.; Wright, J J; Takebe, N; Sharon, E; Hovelson, D; Tomlins, S; Zeng, J; Poorman, K; Malik, N; Gray, R J; Li, S; McShane, L M; Rubinstein, L V; Patton, D; Williams, P M; Hamilton, S R; Conley, B A; Arteaga, C L; Harris, L N; O'Dwyer, P J; Chen, A P; and Flaherty, K T, "Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial." (2022). Department of Medical Oncology Faculty Papers. Paper 178.
https://jdc.jefferson.edu/medoncfp/178
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
35233056
Language
English
Comments
This article is the author’s final published version in npj Precision Oncology, Volume 6, Issue 1, March 2022, Article number 13.
The published version is available at https://doi.org/10.1038/s41698-022-00256-w. Copyright © Mansfield et al.